^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Muphoran (fotemustine)

    i
    Company:
    Servier
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    Apply
    Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma (NCT04083066)
    Phase 4
    Mingzhi Zhang
    Recruiting
    Last update posted :
    09/10/2019
    Initiation :
    09/05/2019
    Primary completion :
    04/01/2023
    Completion :
    04/01/2024
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • cytarabine • pemetrexed • Muphoran (fotemustine) • dexamethasone injection
    Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib (BeyPro1) (NCT01983124)
    Phase 2
    Paola Queirolo
    Completed
    Last update posted :
    01/20/2016
    Initiation :
    02/01/2013
    Primary completion :
    04/01/2014
    Completion :
    09/01/2015
    BRAF
    |
    BRAF V600
    |
    Zelboraf (vemurafenib) • Muphoran (fotemustine)
    A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2) (NCT02460068)
    Phase 3
    Italian Network for Tumor Biotherapy Foundation
    Unknown status
    Last update posted :
    06/02/2015
    Initiation :
    12/01/2012
    Primary completion :
    01/01/2018
    Completion :
    01/01/2020
    BRAF
    |
    BRAF V600E
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Muphoran (fotemustine)